These authors subsequently reported that ALK and KRAS mutations are associated with acquired resistance to crizotinib in ALK-positive NSCLC, suggesting that an ALK mutation detected in plasma can be a useful marker for response monitoring [51]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.